Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN

• Published in: Blood advances Vol. 5; no. 4; pp. 1092 - 1096
• Main Authors: Voorhees, Peter M., Rodriguez, Cesar, Reeves, Brandi, Nathwani, Nitya, Costa, Luciano J., Lutska, Yana, Bobba, Padma, Hoehn, Daniela, Pei, Huiling, Ukropec, Jon, Qi, Ming, Lin, Thomas S., Richardson, Paul G.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 23.02.2021; American Society of Hematology
• Subjects: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Dexamethasone - therapeutic use; Humans; Lenalidomide - therapeutic use; Multiple Myeloma - diagnosis; Multiple Myeloma - drug therapy; Stimulus Report

The phase 2 GRIFFIN study of daratumumab plus lenalidomide/bortezomib/dexamethasone (D-RVd) for transplant-eligible, newly diagnosed multiple myeloma included a safety run-in phase followed by a randomized phase. The ongoing randomized phase has met its prespecified primary end point of an improved...